Additional infusions of mesenchymal stem cells improve response rate in multidrug-resistant GvHD patients.

about

Additional infusions of mesenchymal stem cells improve response rate in multidrug-resistant GvHD patients.

Item

http://www.wikidata.org/entity/Q48135558

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Additional infusions of mesenc ...... idrug-resistant GvHD patients.

@en

Additional infusions of mesenc ...... idrug-resistant GvHD patients.

@nl

type

Item

label

Additional infusions of mesenc ...... idrug-resistant GvHD patients.

@en

Additional infusions of mesenc ...... idrug-resistant GvHD patients.

@nl

prefLabel

Additional infusions of mesenc ...... idrug-resistant GvHD patients.

@en

Additional infusions of mesenc ...... idrug-resistant GvHD patients.

@nl

P1476

Additional infusions of mesenc ...... idrug-resistant GvHD patients.

@en

P2093

A Unal

http://www.w3.org/2001/XMLSchema#string

G Akyol

http://www.w3.org/2001/XMLSchema#string

G Zararsiz

http://www.w3.org/2001/XMLSchema#string

N L Tiren-Verbeet

http://www.w3.org/2001/XMLSchema#string

Z B Gonen

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical applications of mesenchymal stem cells

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

Mesenchymal stem cell treatment for autoimmune diseases: a critical review.

Mesenchymal stem cell as salvage treatment for refractory chronic GVHD

Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group repor

Management of acute graft-versus-host disease.

Gastro-intestinal autoimmunity: preclinical experiences and successful therapy of fistulizing bowel diseases and gut Graft versus host disease by mesenchymal stromal cells.

Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients.

Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.

Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease.

P2888

bmt.2017.1

P304

783-785

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2017.1

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Leylagul Kaynar

Muzaffer Keklik

M Cetin

P577

2017-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084127772

http://www.w3.org/2001/XMLSchema#string

P698

28287643

http://www.w3.org/2001/XMLSchema#string

P921

multiple drug resistance